Treating treatment-naïve Genotype 1 (G1) chronic Hepatitis C (CHC) patients with dual (Peginterferon/Ribavirin, P/R) or triple (P/R + Protease Inhibitor, PI) therapy in Hungary. A…

Background: Introduction of protease inhibitors for the treatment of CHC poses new challenges in countries with limited resources. Cost-effectiveness analysis may provide acceptable compromises for both patients and payers. Aims: To analyse the hypothesis that, initial SOC dual therapy for all naïve G1 CHC patients with an early switch to triple therapy for those with low chance of SVR based on on-treatment viral responses may provide a cost-effective way for payers with no relevant compromise on chance to achieve a sustained viral response (SVR) for patients. Methods. The SVR rates of different regimens were es…